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Abstract
Background & Aims: The I148M variant in PNPLA3 is the major genetic risk factor for 
non-alcoholic fatty liver disease (NAFLD). The liver is enriched with polyunsaturated 
triglycerides (PUFA-TGs) in PNPLA3-I148M carriers. Gene expression data indicate 
that PNPLA3 is liver-specific in humans, but whether it functions in adipose tissue 
(AT) is unknown. We investigated whether PNPLA3-I148M modifies AT metabolism 
in human NAFLD.
Methods: Profiling of the AT lipidome and fasting serum non-esterified fatty acid 
(NEFA) composition was conducted in 125 volunteers (PNPLA3148MM/MI, n = 63; 
PNPLA3148II, n = 62). AT fatty acid composition was determined in 50 volunteers ho-
mozygous for the variant (PNPLA3148MM, n = 25) or lacking the variant (PNPLA3148II, 
n = 25). Whole-body insulin sensitivity of lipolysis was determined using [2H5]glycerol, 
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1  | INTRODUC TION
A common non-synonymous single nucleotide polymorphism 
(rs738409; c.444C>G, p.I148M) in the patatin like phospholipase 
domain containing 3 (PNPLA3, adiponutrin) gene was found in the 
Dallas Heart Study to significantly increase liver fat content in three 
different ethnic groups.1 This finding has since been extensively 
replicated.2 The I148M allele is found in 30%-50% of all subjects3,4 
and increases the risk of both alcoholic and non-alcoholic fatty liver 
disease (NAFLD), including cirrhosis and hepatocellular carcinoma.5
In contrast to NAFLD associated with insulin resistance and 
metabolic syndrome, in which the steatotic liver mainly consists of 
saturated fat, the human liver lipidome is characterized by abso-
lute and relative increases in polyunsaturated triglycerides (TGs) in 
PNPLA3-I148M variant carriers compared with non-carriers.6 The 
I148M variant increases polyunsaturated fatty acid (PUFA) retention 
in liver TGs and decreases incorporation of PUFAs into phospholip-
ids.7 These data closely resemble those of knock-in mice expressing 
a catalytically inactive form of PNPLA3 in the liver (PNPLA3-S47A).8 
Non-esterified fatty acids (NEFAs) resulting from adipose tissue (AT) 
lipolysis are the main source of intrahepatic triglycerides (IHTGs) 
in NAFLD.9 There are no data on whether PNPLA3-I148M exerts 
changes in the lipid composition of AT, as it does in the liver.6,7 
Moreover, the potential impact of the I148M variant on AT lipolysis 
or the composition of NEFAs released from AT has not been studied.
Of interest, PNPLA3 (previously known as adiponutrin) was ini-
tially discovered in mice as a nutritionally regulated transmembrane 
protein thought to be specific to the adipocyte lineage.10,11 In humans, 
the PNPLA3 transcript is, in contrast to findings in mice and rats,12-14 
much more abundant in the liver than in AT.15,16 Concentrations of the 
PNPLA3 protein in the human liver or AT have not, however, been pre-
viously studied. This would be important as efforts are currently ongo-
ing to find therapeutic targets for the treatment of advanced NAFLD in 
genetically predisposed patients.17-19
In the present study, we investigated whether the human AT 
lipidome is modified in a polyunsaturated direction in carriers of 
PNPLA3-I148M compared with non-carriers, as it is in the liver. 
Since this was found to be the case, we next examined whether 
the variant affects AT lipolysis or the composition of circulating 
NEFAs. In addition, we compared PNPLA3 mRNA and protein lev-
els between human liver and subcutaneous AT in a subset of the 
volunteers.
2  | MATERIAL S AND METHODS
2.1 | Volunteers and study design
2.1.1 | Effects of PNPLA3-I148M on AT TG and 
serum NEFA composition
We profiled the AT lipidome and fasting serum NEFA composition 
in 125 consecutively recruited patients undergoing laparoscopic 
and PNPLA3 mRNA and protein levels were measured in subcutaneous AT and liver 
biopsies in a subset of the volunteers.
Results: PUFA-TGs were significantly increased in AT in carriers versus non-carriers 
of PNPLA3-I148M. The variant did not alter the rate of lipolysis or the composition 
of fasting serum NEFAs. PNPLA3 mRNA was 33-fold higher in the liver than in AT 
(P < .0001). In contrast, PNPLA3 protein levels per tissue protein were three-fold 
higher in AT than the liver (P < .0001) and nine-fold higher when related to whole-
body AT and liver tissue masses (P < .0001).
Conclusions: Contrary to previous assumptions, PNPLA3 is highly abundant in AT. 
PNPLA3-I148M locally remodels AT TGs to become polyunsaturated as it does in 
the liver, without affecting lipolysis or composition of serum NEFAs. Changes in AT 
metabolism do not contribute to NAFLD in PNPLA3-I148M carriers.
K E Y W O R D S
adipose tissue, fatty acids, lipidomics, lipolysis, non-alcoholic fatty liver disease, triglycerides
Key points
• The common I148M variant in the gene PNPLA3 is 
the main genetic risk factor for fatty liver disease, but 
whether the variant protein exists or alters lipid metab-
olism in human adipose tissue is unknown.
• We found that the PNPLA3 protein is found at high con-
centrations in human adipose tissue and that carriers of 
the PNPLA3-I148M variant have changes in their adi-
pose tissue lipid composition that mirror those seen in 
the liver.
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bariatric surgery who fulfilled the following inclusion criteria: (a) 
age 18-75 years; (b) no known acute or chronic disease except for 
obesity, type 2 diabetes, NAFLD or hypertension on the basis of 
history, physical examination, electrocardiogram and standard 
laboratory tests (complete blood count, serum creatinine and 
electrolyte concentrations); (c) alcohol consumption <20 g/d for 
women and <30 g/d for men; (d) no clinical or biochemical evi-
dence of liver disease other than NAFLD (such as hepatitis B or C), 
or clinical signs or symptoms of inborn errors of metabolism; (e) 
no history of use of drugs or toxins influencing liver steatosis and 
(f) not pregnant or lactating. We have previously reported data on 
the liver lipidome in a cohort that mostly consisted of the same 
volunteers.6,7 The present cohort differs slightly from that pub-
lished earlier (119 shared volunteers) as a result of technical issues 
in a few of the lipidomic analyses. The volunteers participated in a 
clinical research visit prior to surgery and underwent liver and AT 
biopsies at the time of bariatric surgery (vide infra). PNPLA3 mRNA 
and protein levels between liver and AT samples were compared 
in a subset of 20 of these volunteers, who had enough liver tissue 
left after histological and lipidomic analyses.
2.1.2 | Effects of PNPLA3-I148M on AT fatty acid 
composition and inflammation
In addition to the AT lipidome profiling described above, we ex-
amined the composition of AT fatty acids (FAs) and compared 
gene expression of several pro-inflammatory (MCP-1[monocyte 
chemoattractant protein-1], CD68[CD68 molecule]) and anti-in-
flammatory (TWIST1[twist family bHLH transcription factor 1], 
ADIPOQ[adiponectin, C1Q and collagen domain containing]) mark-
ers in AT in a separate group of 50 volunteers who did not undergo 
bariatric surgery and were known to be homozygous (PNPLA3148II, 
n = 25; PNPLA3148MM, n = 25) based on previous genotyping results. 
The inclusion criteria were as listed above. The volunteers partici-
pated in a clinical research visit during which needle biopsies of ab-
dominal AT were also obtained (vide infra). In addition, on a separate 
visit, liver IHTG content was measured by proton magnetic reso-
nance spectroscopy (1H-MRS).
2.1.3 | Effects of PNPLA3-I148M on in vivo 
AT lipolysis
We recruited 28 non-diabetic volunteers by contacting partici-
pants of prior metabolic studies who were known to be homozy-
gous (PNPLA3148II, n = 19; PNPLA3148MM, n = 9) based on previous 
genotyping results. The inclusion criteria were as listed above. These 
volunteers participated in a clinical research visit as well as in a meta-
bolic study during which whole-body lipolysis was measured using 
[2H5]glycerol in the basal state and during euglycaemic hyperinsuli-
naemia (vide infra). In addition, on a separate visit, liver IHTG content 
was measured by 1H-MRS.
The study was conducted in accordance with the Declaration of 
Helsinki. Each participant provided a written informed consent after 
being explained the nature and potential risks of the study. The ethics 
committee of the Helsinki University Hospital (Helsinki, Finland) ap-
proved the studies.
2.2 | Clinical research visit
The volunteers arrived in the Clinical Research Unit after an over-
night fast (1 week prior to surgery for the bariatric surgery vol-
unteers). At this visit, a history and physical examination were 
performed and fasting blood samples were withdrawn for meas-
urement of blood counts and concentrations of glucose, HbA1c, 
insulin, high-density lipoprotein (HDL) and low-density lipoprotein 
(LDL) cholesterols, TGs,alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), gamma-glutamyl transferase (GGT), 
and creatinine and for genotyping of PNPLA3 as previously de-
scribed.20 Total liver mass was determined from an equation we 
have previously developed.21
2.3 | Adipose tissue and liver biopsies
Immediately at the beginning of the laparoscopic bariatric surgery 
procedure, a wedge biopsy of the liver was taken in addition to a sub-
cutaneous abdominal AT biopsy. The AT sample and approximately 
one-half of the liver sample were immediately snap frozen in liquid 
nitrogen and stored at −80°C until subsequent analysis of molecular 
lipids. The time from obtaining the biopsies until freezing of the sam-
ples in liquid nitrogen was approximately 1 minute. The remainder of 
the liver biopsy was sent to the pathologist for routine histopatholog-
ical assessment using the criteria proposed by Brunt et al.22 For the 
non-surgical volunteers, needle aspiration biopsiesof subcutaneous 
abdominal AT were taken under local anaesthesia with 1% lidocaine 
at the clinical research visit as previously described.23
2.4 | Lipidomic analysis
The AT lipidome was analyzed using an ultra-high performance liquid 
chromatography-quadrupole time-of-flight mass spectrometry sys-
tem (UHPLC-QTOF-MS; Agilent Technologies). In addition to TGs, 
the analysis covered most of the major molecular lipids including 
ceramides, sphingomyelins, phosphatidylcholines, phosphatidyle-
thanolamines and lysophosphatidylcholines. For detailed methodol-
ogy, see Supporting Information.
2.5 | Composition of AT FAs
The analysis of AT FA composition was performed using gas chroma-
tography (GC). AT lipids were extracted according to the method of 
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Folch et al.24 The TG fraction was separated by solid-phase extrac-
tion25 and fatty acid methyl esters (FAMEs) prepared and analyzed 
by GC.26 FAs were identified using a standard containing FAMEs 
ranging from chain length 6 to 24 (Sigma-Aldrich). A FAME standard 
of known composition (AOCS std#6, Thames Restek) and a quality 
control sample (mixture of fatty acids [Sigma-Aldrich] and TGTG 
[MaxEPA fish oil, Seven Seas]) were run alongside each batch of 
samples to check correct peak identification and instrument perfor-
mance. GC results were converted into mol%.
2.6 | Composition of fasting serum NEFAs
The analysis of NEFAs was done using comprehensive two-di-
mensional gas chromatography time-of-flight mass spectrometry 
(GC×GC/TOFMS; Pegasus 4D, LECO Corporation), as described pre-
viously in detail27 and outlined in Supporting Information.
2.7 | Insulin sensitivity of whole-body AT lipolysis
The rate of whole-body lipolysis was measured basally after an over-
night fast and during intravenously maintained euglycaemic hyper-
insulinaemia by infusing [2H5]glycerol as previously described.
28 The 
basal and insulin infusion periods both lasted 120 minutes, and the 
rate of the continuous insulin infusion was 0.4 mU∙kg−1∙min−1. The 
low insulin infusion rate was chosen to maximize the likelihood of 
detecting changes in lipolysis.29
2.8 | Measurement of IHTG content
In the 28 volunteers in whom in vivo lipolysis was measured, and in 
the 50 volunteers from whom a needle biopsy of AT was obtained, 
IHTG content was measured by 1H-MRS, as described.30 To facilitate 
comparison between spectroscopic and histological IHTG measure-
ments, spectroscopic fat percentages were converted to correspond 
to those obtained by liver biopsy using an equation we have previ-
ously published.31
2.9 | Messenger RNA expression
Real-time quantitative polymerase chain reaction (RT-qPCR) was 
performed on reverse-transcribed mRNA isolated from liver and AT 
samples, as described in Supporting Information.
2.10 | Protein levels
Immunoblotting was performed on protein lysates from subcutaneous 
AT and liver tissue specimens. Liver biopsies weighed from 11 to 37 mg 
(23 ± 2 mg), and AT biopsies from 121 to 295 mg (187 ± 10 mg). As a 
positive control, human PNPLA3 cDNA in a pcDNA4HisMax-C vector 
(Invitrogen/Thermo Scientific) was transfected into human hepatoma 
(HuH7) cells using Lipofectamine 2000 (Invitrogen), and total cell lysates 
were harvested at 24 hours post-transfection.32 For protein extraction, 
tissue samples were homogenized in Precellys®24 lysing tubes (Bertin 
Technologies) using 400 µL of lysis buffer containing 50 mmol/L Tris-
HCl, pH 7.4, 150 mmol/L NaCl, 1% NP-40, 0.1% SDS (sodium dodecyl 
sulfate) and protease inhibitor cocktail (Roche Diagnostics). Protein 
concentrations were measured using the bicinchoninic acid (BCA) assay 
(Thermo Fisher Scientific). Proteins (30 μg/well) were separated on 
10% SDS-polyacrylamide gels and transferred to nitrocellulose mem-
branes, which were probed with antibodies against human PNPLA3 
(SAB1401851; Sigma-Aldrich) or β-actin (A2066; Sigma-Aldrich). The 
bound antibodies were detected with enhanced chemiluminescence 
(ECL; Thermo Fisher Scientific). PNPLA3 band intensities were normal-
ized to the band intensities of β-actin, which were analyzed from the 
same membranes.
2.11 | Statistics
Analyses were performed with Statistical Package for the Social 
Sciences (SPSS) version 25 (IBM Corporation) and GraphPad Prism 
version 7.04 (GraphPad Software). The Shapiro-Wilk test was used 
to assess continuous variables for normality. We compared two in-
dependent groups using the unpaired Student's t test or the Mann-
Whitney U test for normally and non-normally distributed variables 
respectively. We used the Pearson's χ2 test or the Fisher's exact test 
as appropriate to evaluate if distribution of categorical variables dif-
fered between two groups. To compare gene and protein expression 
in AT and liver biopsies from the same volunteers, we used the paired 
t test. ΔCt values were used in statistical analyses of the RT-qPCR 
data. For statistical analysis of AT lipidomic and serum NEFA compo-
sition data, missing values were imputed using half mean plus a very 
small amount of random noise. Lipid species with missing values in 
more than 50% of samples were excluded from analyses. Lipidomic 
data were log2-transformed before statistical hypothesis testing, and 
the Benjamini-Hochberg procedure33 was applied to control false 
discovery rate (FDR) at a preselected level of Q = 20%. We report 
unadjusted P values for findings that are determined as discoveries. 
Otherwise, a P < .05 was considered statistically significant.
We have previously shown highly significant differences in 
lipidomic profiles of the liver between PNPLA3-I148M carriers 
(PNPLA3148MM/MI) and non-carriers (PNPLA3148II) in a sample of 125 
volunteers.6 This justifies the similar sample size used for the AT and 
serum analyses, and the comparison of AT FA composition between 
25 homozygous carriers and 25 non-carriers. Regarding the lipoly-
sis study, interindividual variability in insulin suppression of glycerol 
rate of appearance (Ra) was determined based on data we have pre-
viously acquired in obese volunteers.34 Based on these data, we cal-
culated that 9 homozygous carriers and 19 non-carriers are needed 
to detect a 14% between-group difference in insulin suppression 
of glycerolRa using a 2-sided t test with a β value of 0.80 and an α 
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value of 0.05. Power calculations were performed using G*Power 
3.1.9.6.35
3  | RESULTS
3.1 | The AT lipidome is enriched with 
polyunsaturated TGs in PNPLA3-I148M variant 
carriers
Clinical characteristics of the 125 volunteers in whom lipidomic 
analyses of AT were conducted are shown in Table 1. The 63 carriers 
(PNPLA3148MM/MI) were similar to the 62 non-carriers (PNPLA3148II) 
with respect to sex, BMI, body fat, liver fat and circulating 
concentrations of glucose, HbA1C, insulin, TG and HDL and LDL cho-
lesterols. Body weight of the bariatric surgery volunteers was similar 
at the time of the clinical research visit and surgery (130 ± 2 kg vs 
128 ± 2 kg, NS).
Absolute and relative concentrations of polyunsaturated TGs 
containing 5-9 double bonds were significantly higher in the 
PNPLA3148MM/MI group compared with the PNPLA3148II group, sug-
gesting that PUFAs are enriched in TGs in AT of I148M variant 
carriers (Figure 1A; Table S2). The number of double bonds in TGs 
was significantly positively correlated with the ratio of absolute 
TG concentrations between the groups (Figure 1B). A total of 14 
individual polyunsaturated TG species were significantly higher in 
the PNPLA3148MM/MI group (Figure 1C), while we did not observe 
significant changes in saturated TGs. The results were reproduced 
TA B L E  1   Clinical characteristics of the study volunteers.
Variable
AT and serum lipidome (n = 125) In vivo AT lipolysis (n = 28)
PNPLA3148II (n = 62) PNPLA3148MM/MI (n = 63) PNPLA3148II (n = 19) PNPLA3148MM (n = 9)
Age, y 46.4 ± 1.2 49.5 ± 1.0* 50.6 ± 2.4 48.1 ± 4.1
Men 17 (27) 22 (35) 6 (32) 2 (22)
BMI, kg/m2 45.2 ± 0.7 45.4 ± 0.7 30.3 ± 1.1 30.6 ± 2.2
Waist, cm 129.2 ± 1.9 132.0 ± 1.8 98.4 ± 2.8 95.6 ± 5.3
Waist-to-hip ratio 0.93 (0.88-1.00) 0.97 (0.89-1.03) 0.89 (0.88-0.96) 0.88 (0.82-0.95)
SBP, mm Hg 132 (122-144) 135 (124-146) 133 (114-145) 131 (123-150)
DBP, mm Hg 89 (82-94) 92 (84-98) 81 (75-84) 92 (88-97)***
Body fat, % 50 (48-54) 49 (44-54) 34 (26-43) 36 (26-38)
fP-Glucose, mmol/L 5.8 (5.1-6.4) 5.7 (5.2-6.4) 5.8 (5.1-6.0) 5.5 (5.2-5.9)
HbA1c, % 5.7 (5.5-6.3) 5.9 (5.5-6.2) 5.7 (5.3-6.0) 5.7 (5.4-5.9)
HbA1c, mmol/mol 38.8 (36.6-45.4) 39.9 (36.6-44.3) 38.3 (34.4-42.1) 38.8 (35.5-40.7)
fS-Insulin, mU/L 11.8 (7.9-17.1) 12.4 (6.5-18.3) 12.4 (4.1-16.9) 8 (6-12)
fP-HDL cholesterol, mmol/L 1.1 (0.9-1.4) 1.1 (1.0-1.3) 1.5 (1.3-1.9) 1.4 (1.1-1.8)
fP-LDL cholesterol, mmol/L 2.5 ± 0.1 2.5 ± 0.1 3.2 ± 0.2 3.1 ± 0.4
fP-Triglycerides, mmol/L 1.29 (0.96-1.67) 1.28 (1.01-1.62) 1.14 (0.74-1.48) 0.91 (0.79-1.64)
P-ALT, U/L 30 (24-39) 36 (26-46) 30 (16-36) 24 (22-61)
P-AST, U/L 28 (24-33) 32 (26-40)* 25 (22-31) 27 (25-43)
P-GGT, U/L 28 (19-43) 33 (22-48) 25 (19-53) 18 (14-51)
P-Albumin, g/L 38 ± 0.4 38 ± 0.3 40 ± 0.5 39 ± 1.2
B-Platelets,109/L 252 (209-303) 233 (202-285) 253 (221-271) 240 (226-266)
P-Creatinine, µmol/L 67 (58-74) 64 (57-73) 73 (62-75) 76 (61-83)
IHTG, % 5 (0-20) 15 (5-30) 14 (5-31) 24 (20-33)
NASH 7 (11) 16 (25)* NA NA
Type 2 diabetes 25 (40) 33 (52) 0 0
Use of statins 22 (35) 18 (29) 1 (5) 2 (22)
PNPLA3 (CC/CG/GG), n 62/0/0 0/57/6*** 19/0/0 0/0/9***
Note: Data are in n (%), mean ± SEM or median (25th-75th percentiles). Statistical tests used are the unpaired two-tailed Student's t test, Mann-
Whitney U test, Pearson's χ2 test or the Fisher's exact test, as appropriate.
Abbreviations: DBP, diastolic blood pressure; IHTG, intrahepatic triglycerides; NASH, non-alcoholic steatohepatitis; SBP, systolic blood pressure.
*P ≤ .05; 
***P ≤ .001. 
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when excluding volunteers with type 2 diabetes from analyses 
(Figure S1). Previous lipidomic analysis of the liver in mostly the 
same volunteers showed similar PUFA enrichment in liver TGs of 
PNPLA3-I148M carriers.6 We did not observe changes in concen-
trations of ceramides, sphingomyelins, lysophosphatidylcholines, 
phosphatidylcholines or phosphatidylethanolamines between the 
groups (Table S3).
We conducted a further analysis of the composition of me-
dium- to very long-chain FAs in AT samples of homozygous volun-
teers (PNPLA3148II, n = 25; PNPLA3148MM, n = 25). The groups were 
similar with respect to age, sex, BMI and metabolic parameters 
(Table S4). As a whole, there were no significant changes in satu-
rated or monounsaturated FAs between the groups. We observed 
a significant increase in the relative abundance of the omega-3 
PUFA docosapentaenoic acid (DPA, 22:5n-3; P = .028) and a con-
comitant decrease in the omega-6 PUFA arachidonic acid (AA, 
20:4n-6; P = .047) in PNPLA3148MM compared with PNPLA3148II 
volunteers (Figure S2). The omega-6 to omega-3 ratio was signifi-
cantly decreased in the PNPLA3148MM group compared with the 
PNPLA3148II group (4.6 ± 0.2 vs 5.3 ± 0.2, P = .013). As with TGs, we 
observed a significantly positive correlation between the number 
of double bonds in FAs and the ratio of relative FA concentrations 
between the groups (r = 0.50, P = .028, Figure S3).
After observing the changes in PUFA composition of AT FAs, 
we analyzed mRNA concentrations of pro- and anti-inflammatory 
genes in AT from the same volunteers. Levels of pro-inflammatory 
CD68 (1.00 ± 0.14 vs 1.16 ± 0.16 AU) and MCP-1 (1.00 ± 0.10 vs 
0.89 ± 0.09 AU) mRNA were unchanged (all P > .05), whereas levels 
of anti-inflammatory TWIST1 (1.00 ± 0.13 vs 1.58 ± 0.16 AU, P = .01) 
and ADIPOQ (1.00 ± 0.10 vs 1.57 ± 0.38 AU, P = .04) were signifi-
cantly increased in AT of PNPLA3148MM as compared to PNPLA3148II 
volunteers.
3.2 | In vivo AT lipolysis or fasting serum NEFA 
composition is not affected in PNPLA3-I148M 
variant carriers
Clinical characteristics of the 28 volunteers in whom whole-body lipol-
ysis was measured are shown in Table 1. The 9 homozygous carriers 
F I G U R E  1   Adipose tissue TGs are enriched with PUFAs in PNPLA3-I148M variant carriers compared with non-carriers. A, Heatmap 
showing differences in absolute concentrations of various TG species in AT of the PNPLA3148MM/MI group (n = 63) compared with the 
PNPLA3148II group (n = 62). The x-axis denotes the number of double bonds and the y-axis the number of carbons in a TG molecule. Colour 
coding represents log2 of the fold change in TG concentrations between the groups. The brighter the red colour, the higher the increase in 
the absolute concentration of a TG species in the PNPLA3148MM/MI group compared with the PNPLA3148II group. The unpaired two-sample 
Student's t test and the Benjamini-Hochberg method for multiple testing were applied to determine significance after log-transformation 
of the data. *P ≤ .05, **P ≤ .01, ***P ≤ .001. B, Linear regression between the number of double bonds in TGs and log2 of the fold change 
in absolute concentrations of corresponding TGs between PNPLA3148MM/MI and PNPLA3148II groups. C, A volcano plot showing changes 
in individual TGs in the PNPLA3148MM/MI group compared with the PNPLA3148II group. The x-axis denotes log2 of the fold change in the 
concentration of a given TG species between the groups, and the y-axis denotes negative log10 of the P value of an unpaired two-sample 
Student's t test comparing concentrations of a given TG between the groups. The lower gray horizontal dotted line represents P = .05, 
and the upper black horizontal dotted line represents the minimum level of Benjamini-Hochberg corrected significance. Red dots denote 
significantly increased TGs, which are labelled.
(A) (B)
(C)
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(PNPLA3148MM) were similar to the 19 non-carriers (PNPLA3148II) with 
respect to age, sex, BMI, body fat, liver fat and circulating concentra-
tions of glucose, HbA1C, insulin, TG and HDL and LDL cholesterols.
Whole-body [2H5]glycerol Ra in the basal state was 
2.57 ± 0.44 μmol∙kg−1∙min−1 in the PNPLA3148MM group and 
3.02 ± 0.14 μmol∙kg−1∙min−1 in the PNPLA3148II group, with no 
significant difference between the groups (P > .05, Figure 2A). 
During euglycaemic hyperinsulinaemia, glycerol Ra decreased to 
1.51 ± 0.22 μmol∙kg−1∙min−1 in the PNPLA3148MM group, and similarly 
to 1.56 ± 0.08 μmol∙kg−1∙min−1 in the PNPLA3148II group (P > .05, 
Figure 2B). The percentage suppression of glycerol Ra (i.e. lipolysis) 
by insulin did not significantly differ between PNPLA3148MM and 
PNPLA3148II volunteers (43.3 ± 5.0 vs 47.6 ± 2.4%, P > .05; Figure 2C).
We profiled the composition of fasting serum NEFAs in the same 
125 volunteers in whom lipidomic studies of AT were conducted, 
as described above. After correcting for multiple testing, we found 
F I G U R E  2   The PNPLA3-I148M variant does not affect the rate or insulin suppression of AT lipolysis. Glycerol Ra in the PNPLA3
148II 
(blue bars, n = 19) and PNPLA3148MM (red bars, n = 9) groups in the basal state (A) and during euglycaemic hyperinsulinaemia (B), and the 
percentage suppression of glycerol Ra during the hyperinsulinaemic clamp (C). Bars represent means ± SEM. The unpaired two-sample 
Student's t test was used to determine significance
(A) (B) (C)
F I G U R E  3   PNPLA3 is found abundantly in human AT. A, Expression of PNPLA3 mRNA in the human liver (blue bars, n = 20) and AT (red 
bars, n = 20) shown as means ± 95% confidence intervals. All measurements were performed twice. Expression data were normalized either 
to the housekeeping gene 36B4, ACTB, or the geometric mean of their expression levels. Expression in the liver normalized to 36B4 was 
set to equal 1. B, Representative immunoblots from eight volunteers are shown. Positive controls from PNPLA3-overexpressing HuH7 cell 
lysates (oex HuH7) are shown in the first lanes. The encoded protein has a slightly higher molecular mass than the endogenous PNPLA3, 
since it carries a His6 tag and an Xpress antibody epitope. C-E, PNPLA3 protein levels in the human liver (blue boxes, n = 20) versus AT (red 
boxes, n = 20). Boxes show median as a horizontal line and the bounds of the boxes represent interquartile ranges. Whiskers extend to 
minimum and maximum values. Data are shown as either PNPLA3 levels per milligram of tissue protein (C), per milligram of tissue (D) or as 
whole-body levels of PNPLA3 (E) calculated by multiplying the amount of PNPLA3 per milligram of tissue by the estimated organ weight. 
The paired two-sample Student's t test was used to determine significance. ***P ≤ .001
(A)
(C) (D) (E)
(B)
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no significant differences in absolute or relative concentrations of 
fasting serum NEFAs between the PNPLA3148MM/MI and PNPLA3148II 
groups (Table S5).
3.3 | Expression of PNPLA3 mRNA is markedly 
higher in the liver compared to AT, but the PNPLA3 
protein is more abundant in AT
The change we observed in the AT lipidome in carriers of PNPLA3-
I148M was unexpected as mRNA expression has been shown to 
be very low in human AT as compared to the liver.15,16 There are, 
however, no protein data available. Therefore, we investigated 
PNPLA3 protein levels in tissue samples of AT and the liver in a 
subset of 20 volunteers (mean age 46.0 ± 1.9 years, mean BMI 
45.6 ± 1.4 kg/m2).
Quantitative PCR analysis showed that PNPLA3 mRNA expres-
sion was markedly higher in the liver compared to AT. Normalized to 
the mRNA levels of the reference genes 36B4 and ACTB, expression 
of PNPLA3 mRNA was on average 33-fold higher in the liver than in 
AT (P < .0001; Figure 3A).
PNPLA3 antibody specificity was confirmed by immunoblotting 
mock-transfected HuH7 cell lysates and cells transfected with hu-
manPNPLA3 (Figure S4). Immunoblotting (Figure 3B) revealed that 
the level of PNPLA3 protein was three-fold higher in AT than the 
liver (P < .0001; Figure 3C), and two-fold higher when normalized to 
β-actin levels (P < .0001). Total protein concentration was eight-fold 
higher in the liver samples than the AT samples (P < .0001). Thus, 
per milligram of tissue, the concentration of PNPLA3 was three-fold 
higher in the liver than in AT (P < .0001) (Figure 3D). We estimated 
whole-body levels of PNPLA3 in AT and the liver by multiplying the 
concentration of PNPLA3 per milligram of tissue by the estimated 
organ weight. Average liver mass was 2.3 ± 0.2 kg, and average AT 
mass was 54.4 ± 2.9 kg. Assuming homogenous levels of PNPLA3 in 
the liver and in AT depots, whole-body levels of PNPLA3 were nine-
fold higher in AT than the liver (P < .0001) (Figure 3E).
4  | DISCUSSION
The present series of studies were undertaken to investigate 
whether the PNPLA3-I148M variant changes AT TG composition, as 
it does in the liver. Since this was found to be the case, we next de-
termined whether this change in AT TG composition was reflected in 
AT FA composition, in vivo AT lipolysis, or the composition of fasting 
serum NEFAs released from AT. As previously reported for the liver 
lipidome in the same volunteers,6 the I148M variant was associated 
with a more polyunsaturated TG composition of AT, while not influ-
encing the rate of AT lipolysis or the composition of NEFAs released 
from AT. We found human AT to contain approximately nine-fold 
more PNPLA3 protein than the liver at the level of the whole body.
Polyunsaturated TGs were enriched in both absolute and relative 
terms in the PNPLA3148MM/MI compared with the PNPLA3148II group 
when we profiled the AT lipidome from biopsies of 125 volunteers 
(Figure 1). This marked increase in polyunsaturated TG species in 
AT closely resembles our previous findings in the liver lipidome of 
mostly the same volunteers, which was also enriched with polyun-
saturated TGs in I148M variant carriers compared with non-carri-
ers.6 Although UHPLC-QTOF-MS has a high detection sensitivity 
and is capable of detecting sub-ppm masses, this method only mea-
sures the total mass and the number of double bonds of individual 
TGs. To investigate the relative amounts of specific FA constituents 
in AT TGs, we conducted a further GC analysis of AT needle biopsies 
from 50 homozygous volunteers. These data essentially confirmed 
the changes seen in TG composition, indicating an accumulation of 
PUFAs in AT of PNPLA3-I148M carriers (Figures S2 and S3).
We have recently shown, with the use of stable isotope FA trac-
ers, that the PNPLA3-I148M variant causes retention of PUFAs in 
TGs and a concomitant deficiency of polyunsaturated phosphatidyl-
cholines (PCs) in the human liver.7 This was also observed in vitro 
in stable human cell lines where incubation of cells with PUFAs 
induced lipid droplet accumulation in both homozygous PNPLA3-
I148M knock-in and PNPLA3 knock-out cells but not in wild-type 
cells.7 These data are similar to those by Mitsche et al. in knock-in 
mice expressing the catalytically inactive S47A variant.8 In the latter 
study, it was proposed that PNPLA3 normally acts as a transacylase 
and transfers PUFAs from TGs to PCs. The absence of this function 
in the PNPLA3-S47A knock-in mice apparently resulted in an en-
richment of their livers with PUFA-containing TGs and a deficiency 
of PUFA-containing PCs. These data would support the idea that 
PNPLA3-I148M is a loss-of-function mutation in humans. Consistent 
with retention of PUFAs in the liver, PUFAs are also deficient in VLDL 
which transfers TG-bound FAs into AT and other peripheral tissues.7 
Thus, the excess of polyunsaturated TGs in AT cannot be secondary 
to their transfer from the liver to AT in VLDL.
Adipose tissue is chronically inflamed in obese subjects, which 
may contribute to insulin resistance and the development of 
NAFLD.36-38 We have previously shown that AT inflammation is 
absent in PNPLA3-I148M carriers with NAFLD compared with 
non-carriers and suggested that this may contribute to the lack of in-
sulin resistance in carriers of PNPLA3-I148M.39 In the present study, 
the omega-6- to omega-3-PUFA ratio was lower in AT of carriers 
versus non-carriers of PNPLA3-I148M, reflecting lower concentra-
tions of omega-6 AA and higher concentrations of omega-3 DPA 
(Figure S2). Expression of anti-inflammatory genes was increased 
and pro-inflammatory genes unchanged in variant carriers compared 
with non-carriers. These changes are anti- rather than pro-inflam-
matory. Arachidonic acid is a precursor of eicosanoids that mediate 
the production of pro-inflammatory cytokines,40 while DPA is syn-
thesized from a precursor of anti-inflammatory eicosanoids.40 An 
increased omega-6 to omega-3 ratio is associated with pro-inflam-
matory states and impaired function of metabolically active tissues 
such as the liver and AT.40 The present data thus suggest that car-
riers of the PNPLA3-I148M variant possess metabolically healthy, 
PUFA-enriched AT that does not harbour pro-inflammatory proper-
ties. Interestingly, AT enriched with PUFA was shown in the Scottish 
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Heart Health Extended Cohort study to decrease the risk of future 
cardiovascular events, independent of other known risk factors.41 
The PNPLA3-I148M variant has also been associated with protec-
tion against cardiovascular sequelae in NAFLD.42-45
The composition of subcutaneous AT is affected by long-term 
changes in dietary FA intake.46 A limitation of this study is that we 
did not have dietary data available on the volunteers in whom lip-
idomic analyses of AT were conducted. We did, however, obtain 
careful dietary records in a recent study in which we demonstrated 
retention of PUFAs in the liver of PNPLA3-I148M carriers.7 In this 
study, the changes in PUFA metabolism were entirely attributed to 
the PNPLA3 genotype rather than diet. The changes in AT TGs in the 
present study also closely mirror those seen in the liver. Thus, it is 
unlikely that the PUFA enrichment in AT would be caused by dietary 
differences between the groups.
Rates of in vivo lipolysis measured in the basal state and during 
euglycaemic hyperinsulinaemia using [2H5]glycerol were similar in 
the PNPLA3148MM and PNPLA3148II groups (Figure 2). This analysis 
had 80% power to detect a 14% between-group difference in insu-
lin suppression of glycerol Ra. The turnover rates of individual FAs 
differ significantly,47 which is why we used [2H5]glycerol rather 
than an individual FA such as 13C-palmitate to trace lipolysis. We 
also determined the composition of circulating NEFAs in 125 vol-
unteers, since changes in the AT lipidome would be expected to 
reflect serum NEFA composition in the fasted state. We found no 
significant differences in serum NEFAs between the PNPLA3148II 
and PNPLA3148MM/MI groups (Table S5). Overall, these data imply 
that the increase in polyunsaturated IHTGs in I148M variant car-
riers is not as a result of increased NEFA delivery from AT to the 
liver.
Because we unexpectedly found the AT lipid composition to dif-
fer between carriers and non-carriers of the PNPLA3-I148M vari-
ant, we compared gene and protein expression of PNPLA3 between 
liver and AT samples in a small subset of the volunteers. PNPLA3 
mRNA was markedly higher in the human liver than in subcutaneous 
AT (Figure 3), consistent with previous studies.15,16 This is in stark 
contrast to mice in which PNPLA3 mRNA expression is unequivocally 
highest in AT depots and only small amounts of mRNA can be de-
tected in other tissues, including the liver.12-14 These contradictory 
results between human and mouse studies are yet to be explained 
but may reflect physiological differences between species. Despite 
higher gene expression in the liver, the PNPLA3 protein was much 
more abundant in AT than the liver (Figure 3). Importantly, we ex-
trapolated AT protein expression from one subcutaneous AT biopsy 
to the whole body, which assumes homogenous expression in all 
compartments of these tissues. This finding challenges the previ-
ous liver-centric view of the protein and its function in humans and 
raises the question as to whether polymorphisms in PNPLA3 could 
introduce significant alterations in human lipid metabolism via extra-
hepatic pathways.
We conclude that the PNPLA3 protein is found not only in the 
human liver but also highly abundantly in AT. This is contrary to pre-
vious assumptions, according to which PNPLA3 is a liver-specific 
protein in humans. The PNPLA3-I148M variant alters AT lipid com-
position in a similar fashion as in the liver,6 that is, the lipidome is 
significantly enriched with polyunsaturated TGs. This change in AT 
lipid composition cannot explain the higher polyunsaturated IHTG 
content in PNPLA3-I148M carriers, since the variant does not affect 
the rate of AT lipolysis or the composition of NEFAs released from 
AT. We propose that the PNPLA3-I148M variant remodels TG com-
position in both the liver and AT independently, with the enrichment 
of PUFAs. This human knowledge is relevant as efforts are currently 
ongoing to develop novel pharmaceuticals to treat NAFLD caused 
by PNPLA3-I148M.17-19 On the basis of our findings, we suggest 
that therapies aimed at ameliorating NAFLD due to PNPLA3-I148M 
should be liver-specific.
ACKNOWLEDG EMENTS
We gratefully acknowledge volunteers for their help. We thank Aila 
Karioja-Kallio, Päivi Ihamuotila and Mia Urjansson for their excellent 
technical assistance.
LH is a British Heart Foundation Senior Research Fellow in Basic 
Science.
CONFLIC TS OF INTERE S T
The authors have declared that no conflicts of interest exist.
ORCID
Sami Qadri  https://orcid.org/0000-0001-9313-9324 
Susanna Lallukka-Brück  https://orcid.org/0000-0002-9775-6669 
Panu K. Luukkonen  https://orcid.org/0000-0003-2085-679X 
You Zhou http://orcid.org/0000-0002-1743-1291 
Amalia Gastaldelli  https://orcid.org/0000-0003-2594-1651 
Anne K. Penttilä  https://orcid.org/0000-0001-7480-8959 
Matej Orešič  https://orcid.org/0000-0002-2856-9165 
Tuulia Hyötyläinen  https://orcid.org/0000-0002-1389-8302 
Leanne Hodson  https://orcid.org/0000-0002-2648-6526 
Vesa M. Olkkonen  https://orcid.org/0000-0001-5553-7997 
Hannele Yki-Järvinen  https://orcid.org/0000-0001-6766-1549 
R E FE R E N C E S
 1. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 
confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 
2008;40(12):1461-1465.
 2. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M 
variant of patatin-like phospholipase domain containing 3 gene 
(PNPLA3) on the susceptibility and histological severity of nonalco-
holic fatty liver disease. Hepatology. 2011;53(6):1883-1894.
 3. Romeo S, Sentinelli F, Cambuli VM, et al. The 148M allele of the 
PNPLA3 gene is associated with indices of liver damage early in life. 
J Hepatol. 2010;53(2):335-338.
 4. Hyysalo J, Männistö VT, Zhou Y, et al. A population-based study on 
the prevalence of NASH using scores validated against liver histol-
ogy. J Hepatol. 2014;60(4):839-846.
 5. Trepo E, Romeo S, Zucman-Rossi J, Nahon P. PNPLA3 gene in liver 
diseases. J Hepatol. 2016;65(2):399-412.
 6. Luukkonen PK, Zhou Y, Sädevirta S, et al. Hepatic ceramides disso-
ciate steatosis and insulin resistance in patients with non-alcoholic 
fatty liver disease. J Hepatol. 2016;64(5):1167-1175.
10  |     QADRI et Al.
 7. Luukkonen PK, Nick A, Hölttä-Vuori M, et al. Human PNPLA3-
I148M variant increases hepatic retention of polyunsaturated fatty 
acids. JCI. Insight. 2019;4(16).
 8. Mitsche MA, Hobbs HH, Cohen JC. Patatin-like phospholipase do-
main-containing protein 3 promotes transfer of essential fatty acids 
from triglycerides to phospholipids in hepatic lipid droplets. J Biol 
Chem. 2018;293(18):6958-6968.
 9. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, 
Parks EJ. Sources of fatty acids stored in liver and secreted via li-
poproteins in patients with nonalcoholic fatty liver disease. J Clin 
Invest. 2005;115(5):1343-1351.
 10. Baulande S, Lasnier F, Lucas M, Pairault J. Adiponutrin, a transmem-
brane protein corresponding to a novel dietary- and obesity-linked 
mRNA specifically expressed in the adipose lineage. J Biol Chem. 
2001;276(36):33336-33344.
 11. Polson DA, Thompson MP. Adiponutrin mRNA expression in white 
adipose tissue is rapidly induced by meal-feeding a high-sucrose 
diet. Biochem Biophys Res Commun. 2003;301(2):261-266.
 12. Lake AC, Sun Y, Li J-L, et al. Expression, regulation, and triglycer-
ide hydrolase activity of Adiponutrin family members. J Lipid Res. 
2005;46(11):2477-2487.
 13. Kershaw EE, Hamm JK, Verhagen LA, Peroni O, Katic M, Flier JS. 
Adipose triglyceride lipase: function, regulation by insulin, and com-
parison with adiponutrin. Diabetes. 2006;55(1):148-157.
 14. Villena JA, Roy S, Sarkadi-Nagy E, Kim KH, Sul HS. Desnutrin, an 
adipocyte gene encoding a novel patatin domain-containing pro-
tein, is induced by fasting and glucocorticoids: ectopic expres-
sion of desnutrin increases triglyceride hydrolysis. J Biol Chem. 
2004;279(45):47066-47075.
 15. Wilson PA, Gardner SD, Lambie NM, Commans SA, Crowther DJ. 
Characterization of the human patatin-like phospholipase family. J 
Lipid Res. 2006;47(9):1940-1949.
 16. Huang Y, He S, Li JZ, et al. A feed-forward loop amplifies nu-
tritional regulation of PNPLA3. Proc Natl Acad Sci USA. 
2010;107(17):7892-7897.
 17. BasuRay S, Wang Y, Smagris E, Cohen JC, Hobbs HH. Accumulation 
of PNPLA3 on lipid droplets is the basis of associated hepatic ste-
atosis. Proc Natl Acad Sci USA. 2019;116(19):9521-9526.
 18. Lindén D, Ahnmark A, Pingitore P, et al. Pnpla3 silencing with 
antisense oligonucleotides ameliorates nonalcoholic steatohep-
atitis and fibrosis in Pnpla3 I148M knock-in mice. Mol Metab. 
2019;22:49-61.
 19. Kumashiro N, Yoshimura T, Cantley JL, et al. Role of patatin-like 
phospholipase domain-containing 3 on lipid-induced hepatic steato-
sis and insulin resistance in rats. Hepatology. 2013;57(5):1763-1772.
 20. Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-al-
coholic fatty liver disease and liver fat using metabolic and genetic 
factors. Gastroenterology. 2009;137(3):865-872.
 21. Bian H, Hakkarainen A, Zhou Y, Lundbom N, Olkkonen VM, Yki-
Jarvinen H. Impact of non-alcoholic fatty liver disease on liver vol-
ume in humans. Hepatol Res. 2015;45(2):210-219.
 22. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri 
BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for 
grading and staging the histological lesions. Am J Gastroenterol. 
1999;94(9):2467-2474.
 23. Yki-Jarvinen H, Taskinen MR, Koivisto VA, Nikkila EA. Response of 
adipose tissue lipoprotein lipase activity and serum lipoproteins to 
acute hyperinsulinaemia in man. Diabetologia. 1984;27(3):364-369.
 24. Folch J, Lees M, Sloane Stanley GH. A simple method for the isola-
tion and purification of total lipides from animal tissues. J Biol Chem. 
1957;226(1):497-509.
 25. Burdge GC, Wright P, Jones AE, Wootton SA. A method for sepa-
ration of phosphatidylcholine, triacylglycerol, non-esterified fatty 
acids and cholesterol esters from plasma by solid-phase extraction. 
Br J Nutr. 2000;84(5):781-787.
 26. Evans K, Burdge GC, Wootton SA, Clark ML, Frayn KN. Regulation 
of dietary fatty acid entrapment in subcutaneous adipose tissue 
and skeletal muscle. Diabetes. 2002;51(9):2684-2690.
 27. Castillo S, Mattila I, Miettinen J, Oresic M, Hyotylainen T. Data anal-
ysis tool for comprehensive two-dimensional gas chromatography/
time-of-flight mass spectrometry. Anal Chem. 2011;83(8):3058-3067.
 28. Sevastianova K, Kotronen A, Gastaldelli A, et al. Genetic vari-
ation in PNPLA3 (adiponutrin) confers sensitivity to weight 
loss-induced decrease in liver fat in humans. Am J Clin Nutr. 
2011;94(1):104-111.
 29. Nurjhan N, Campbell PJ, Kennedy FP, Miles JM, Gerich JE. Insulin 
dose-response characteristics for suppression of glycerol release and 
conversion to glucose in humans. Diabetes. 1986;35(12):1326-1331.
 30. Ryysy L, Hakkinen AM, Goto T, et al. Hepatic fat content and insulin 
action on free fatty acids and glucose metabolism rather than insulin 
absorption are associated with insulin requirements during insulin 
therapy in type 2 diabetic patients. Diabetes. 2000;49(5):749-758.
 31. Kotronen A, Vehkavaara S, Seppala-Lindroos A, Bergholm R, Yki-
Jarvinen H. Effect of liver fat on insulin clearance. Am J Physiol 
Endocrinol Metab. 2007;293(6):E1709-E1715.
 32. Perttilä J, Huaman-Samanez C, Caron S, et al. PNPLA3 is regulated 
by glucose in human hepatocytes, and its I148M mutant slows 
down triglyceride hydrolysis. Am J Physiol-Endocrinol Metabolism. 
2012;302(9):E1063-E1069.
 33. Hochberg Y, Benjamini Y. More powerful procedures for multiple 
significance testing. Stat Med. 1990;9(7):811-818.
 34. Luukkonen PK, Sädevirta S, Zhou Y, et al. Saturated fat is more 
metabolically harmful for the human liver than unsaturated fat or 
simple sugars. Diabetes Care. 2018;41(8):1732-1739.
 35. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible sta-
tistical power analysis program for the social, behavioral, and bio-
medical sciences. Behav Res Methods. 2007;39(2):175-191.
 36. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a 
crucial role in the development of obesity-related insulin resistance. 
J Clin Invest. 2003;112(12):1821-1830.
 37. Weisberg SP, McCann D, Desai M, et al. Obesity is associated 
with macrophage accumulation in adipose tissue. J Clin Invest. 
2003;112(12):1796-1808.
 38. Tordjman J, Divoux A, Prifti E, et al. Structural and inflam-
matory heterogeneity in subcutaneous adipose tissue: rela-
tion with liver histopathology in morbid obesity. J Hepatol. 
2012;56(5):1152-1158.
 39. Lallukka S, Sevastianova K, Perttilä J, et al. Adipose tissue is in-
flamed in NAFLD due to obesity but not in NAFLD due to genetic 
variation in PNPLA3. Diabetologia. 2013;56(4):886-892.
 40. Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, 
and nonalcoholic fatty liver disease. Annu Rev Nutr. 2013;33:231-248.
 41. Woodward M, Tunstall-Pedoe H, Batty GD, Tavendale R, Hu FB, 
Czernichow S. The prognostic value of adipose tissue fatty acids 
for incident cardiovascular disease: results from 3944 subjects 
in the Scottish Heart Health Extended Cohort Study. Eur Heart J. 
2011;32(11):1416-1423.
 42. Liu DJ, Peloso GM, Yu H, et al. Exome-wide association study of plasma 
lipids in >300,000 individuals. Nat Genet. 2017;49(12):1758-1766.
 43. Simons N, Isaacs A, Koek GH, Kuc S, Schaper NC, Brouwers M. 
PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery 
disease. Gastroenterology. 2017;152(4):912-913.
 44. Xia MF, Lin HD, Chen LY, et al. The PNPLA3 rs738409 C>G vari-
ant interacts with changes in body weight over time to aggravate 
liver steatosis, but reduces the risk of incident type 2 diabetes. 
Diabetologia. 2019;62(4):644-654.
 45. Meffert PJ, Repp KD, Völzke H, et al. The PNPLA3 SNP rs738409: 
G allele is associated with increased liver disease-associated mor-
tality but reduced overall mortality in a population-based cohort. J 
Hepatol. 2018;68(4):858-860.
     |  11QADRI et Al.
 46. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adi-
pose tissue and blood in humans and its use as a biomarker of di-
etary intake. Prog Lipid Res. 2008;47(5):348-380.
 47. Hagenfeldt L. Turnover of individual free fatty acids in man. Fed 
Proc. 1975;34(13):2246-2249.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Qadri S, Lallukka-Brück S, 
Luukkonen PK, et al. The PNPLA3-I148M variant increases 
polyunsaturated triglycerides in human adipose tissue. Liver 
Int. 2020;00:1–11. https://doi.org/10.1111/liv.14507
